We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Theraclone Partners with Gilead Sciences for Neutralizing HIV Antibody Technology

By LabMedica International staff writers
Posted on 13 Aug 2014
Print article
Theraclone Sciences, Inc. (Seattle, WA, USA), a therapeutic antibody discovery and development company, has entered into an agreement with Gilead Sciences, Inc. (Foster City, CA, USA), under which Gilead received an exclusive license to develop and commercialize products integrating Theraclone’s broadly neutralizing HIV-antibodies for therapeutic applications in HIV.

These neutralizing antibodies (bNAbs) were discovered in collaboration with the International AIDS Vaccine Initiative (IAVI; New York, NY, USA) and The Scripps Research Institute (La Jolla, CA, USA) using Theraclone’s proprietary I-STAR (in-situ therapeutic antibody rescue) technology. The I-STAR technology allows for the rapid testing of tens of thousands of fully human antibodies to find those with exceptional biologic functions and activities.

“Through our innovative I-STAR technology, we are able to uncover unique antibodies that have the capacity to neutralize viruses, such as HIV, that are known to mutate and evade current therapies,” said Clifford J. Stocks, chief executive officer of Theraclone. “We look forward to collaborating with Gilead on the development of new therapies to address HIV infection.”

Theraclone is a biopharmaceutical company focused on the discovery and development of novel, monoclonal antibody therapeutics for diseases that are deemed a considerable health threat. Theraclone utilizes its proprietary antibody discovery technology, I-STAR to identify rare fully human antibodies, from immunologically relevant human study participants, that may be developed into antibody product candidates that are potentially safer and more effective than current therapies, or that address an unmet need.

With a primary focus on cancer and infectious disease, Theraclone has a range of antibody programs at preclinical and clinical development stage targeting serious medical disorders with a significant unmet medical need including: triple negative and endocrine treatment-resistant HER-2-negative breast cancer; infectious disease-associated cancers; immune profiling of cancer patients treated with immunomodulators, checkpoint inhibitors or cancer vaccines; and Gram-negative multidrug resistant bacteria.

TCN-032 is a recombinant fully human monoclonal antibody for the treatment of patients hospitalized with serious influenza that has shown statistically significant reduction in viral load and improvement of clinical symptom scores in a phase 2a viral challenge model.

Related Links:

Theraclone Sciences
Gilead Sciences
International AIDS Vaccine Initiative


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.